Who
Xichen Lin
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Structure Therapeutics.
In numbers
- Trades disclosed
- 82
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 15 Mar 2024
- Last trade
- 1 Sep 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,05817,817 at $0.34 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code C | —17,817 at $0.00 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,817 at $0.00 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,817 at $0.00 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —5,939 at $0.00 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | $60K1,300 at $45.86 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | $214K4,539 at $47.20 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | $4,783100 at $47.83 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —5,939 at $0.00 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | $60K1,300 at $45.86 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | $214K4,539 at $47.20 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | $4,783100 at $47.83 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,05817,817 at $0.34 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code C | —17,817 at $0.00 | filing |
| 18 Aug 2026filed 19 Aug 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code M | $4,01811,817 at $0.34 | filing |
| 18 Aug 2026filed 19 Aug 2026 | GPCR Structure TherapeuticsBiotechnology | SEC FORM 4 Code C | —11,817 at $0.00 | filing |
| 18 Aug 2026filed 19 Aug 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,817 at $0.00 | filing |
| 18 Aug 2026filed 19 Aug 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,817 at $0.00 | filing |
| 18 Aug 2026filed 19 Aug 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,939 at $0.00 | filing |
| 18 Aug 2026filed 19 Aug 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code S | $160K3,020 at $53.13 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.